These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2120080)

  • 1. Non-tryptophan fluorescence and high molecular weight protein formation in lens crystallins of rats with chronic galactosemia: prevention by the aldose reductase inhibitor sorbinil.
    Nagaraj RH; Monnier VM
    Exp Eye Res; 1990 Oct; 51(4):411-8. PubMed ID: 2120080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase.
    Nagaraj RH; Prabhakaram M; Ortwerth BJ; Monnier VM
    Diabetes; 1994 Apr; 43(4):580-6. PubMed ID: 8138064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue-specific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia. Relationship to pentosidine cross-links.
    Richard S; Tamas C; Sell DR; Monnier VM
    Diabetes; 1991 Aug; 40(8):1049-56. PubMed ID: 1907247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorbinil protection of lens protein components and cell hydration during diabetic cataract formation.
    Beyer-Mears A; Cruz E; Nicolas-Alexandre J; Varagiannis E
    Pharmacology; 1982; 24(3):193-200. PubMed ID: 6803262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
    Kern TS; Engerman RL
    Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
    Tilton RG; Pugliese G; LaRose LS; Faller AM; Chang K; Province MA; Williamson JR
    J Diabet Complications; 1991; 5(4):230-7. PubMed ID: 1779018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK; Hanwell MA; Satchell PM; Handelsman DJ; Turtle JR
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of Zopolrestat and Sorbinil on lens myo-inositol influx.
    Beyer-Mears A; Diecke FP; Mistry K; Cruz E
    Pharmacology; 1997 Feb; 54(2):76-83. PubMed ID: 9088040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL; Kern TS
    Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
    Vinores SA; Campochiaro PA
    Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors.
    Lightman S; Rechthand E; Terubayashi H; Palestine A; Rapoport S; Kador P
    Diabetes; 1987 Nov; 36(11):1271-5. PubMed ID: 3117606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
    Das A; Frank RN; Zhang NL; Samadani E
    Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the aldose reductase inhibitor sorbinil on the isolated cultured rat lens.
    Yeh LA; Rafford CE; Beyer TA; Hutson NJ
    Metabolism; 1986 Apr; 35(4 Suppl 1):4-9. PubMed ID: 3083208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of hyperbaric oxygen on the crystallins of cultured rabbit lenses: a possible catalytic role for copper.
    Padgaonkar VA; Leverenz VR; Fowler KE; Reddy VN; Giblin FJ
    Exp Eye Res; 2000 Oct; 71(4):371-83. PubMed ID: 10995558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of naphthalene-1,2-dihydrodiol-induced lens protein modifications by structurally diverse aldose reductase inhibitors.
    Sato S; Sugiyama K; Lee YS; Kador PF
    Exp Eye Res; 1999 May; 68(5):601-8. PubMed ID: 10328974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of stage-I sugar cataract by Sorbinil, an aldose reductase inhibitor.
    Beyer-Mears A; Cruz E; Varagiannis E
    Pharmacology; 1985; 31(2):88-96. PubMed ID: 3927328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil.
    Kato K; Nakayama K; Mizota M; Miwa I; Okuda J
    Chem Pharm Bull (Tokyo); 1991 Jun; 39(6):1540-5. PubMed ID: 1934175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase inhibitors and prevention of galactose cataracts in rats.
    Unakar N; Tsui J; Johnson M
    Invest Ophthalmol Vis Sci; 1989 Jul; 30(7):1623-32. PubMed ID: 2545646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
    Datiles M; Fukui H; Kuwabara T; Kinoshita JH
    Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
    Datiles MB; Kador PF; Kashima K; Kinoshita JH; Sinha A
    Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2201-4. PubMed ID: 2122961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.